Publications

·    Co-inventor on 3 U.S. patents/patent applications.

1. Hammill JT, Kadayat TM, Scott DC, Singh B, Schulman, BA, Begely KL, Moseley, TJ, Kovalic LC, Guy, RK. “Compositions, and methods for inhibiting DCN1-UBC12 Interaction” US Patent 2023/025340.

2. Chin J, Kyungjin JU, Kim J, Cho SJ, Kadayat TM. "3, 4-dihydroquinoxaline-2-carboximide derivative compound and pharmaceutical composition comprising same for preventing or treating cancer disease.  US Patent 18/852,493. 2025.

3. Chin J, Kadayat TM, Cho SJ, Jeon YH, Kim J, Kwon S, HWANG H, LEE JE, Kim N, JUNG K, Kim S, inventors. Thiadiazole compound, and pharmaceutical composition for preventing or treating inflammatory diseases, including same. US patent 18/847,249. 2025.  

·   >45 Publications in peer-reviewed journals, 23 First Author, Google Scholar Citation: 1125

Major Publication (*Equal Contribution, #Corresponding author)

      1.  Kadayat TM et al. “Bridging gaps in pharmacy education in Nepal: A qualitative exploration of curriculum challenges and future directions” J. Educ. Eval. Health Prof. 2025 (Submitted)

     2.  Kadayat TM et al. “Synthesis and biological evaluation of 4, 7, 9-trisubstituted benzoxazepines as antileishmanial agents” Bioorg. Med. Chem. Lett. 114 (2024), 130003. Link

3.   *Carrillo AK, *Kadayat TM et al. “Antitrypanosomal chloronitrobenzamides” J.  Med. Chem. 67 (2024), 3437. Link

4.   *Kim J, *Kadayat TM et al. “Discovery of the therapeutic potential of PPARd agonist bearing 1,3,4- thiadiazole in inflammatory disorders” Eur. J.  Med. Chem. 279 (2024), 116856. Link

5.   Kim HJ, Kim H, Song J, Hong JY, Lee EH, Jung K, Kwon S, Kadayat TM et al. “Highly potent and selective PPARδ agonist reverses memory deficits in mouse models of Alzheimer's disease Theragnostics 14 (2024), 6088. Link

6.       *Kim HS, *Ortiz D, *Kadayat TM et al. “Optimization of Orally Bioavailable Antileishmanial 2,4,5-Trisubstituted Benzamides” J.  Med. Chem.  66 (2023), 7374. Link

7.       Shrestha A, Kim N, Lee SJ, Jeon YH, Cho SJ, #Kadayat TM (#Co-corresponding author), #Chin J “Targeting NSD Family of Histone Lysine Methyltransferases: Recent Progress and Perspective” J. Med. Chem. 64 (2021), 14913. Link

8.       Kadayat TM et al. “Antioxidative and Anti-inflammatory activity of Psiguadial B and its halogenated analogues as potential neuroprotective agents” Bioorg. Chem. 113 (2021), 105027. Link

9.       Kadayat TM et al. “Targeting Peroxisome Proliferator-activated Receptor delta (PPARd) agonist: A Medicinal Chemistry Perspective” J. Med. Chem. 63 (2020), 10109. Link

10.    Kadayat TM et al. “Discovery and Biological Evaluations of Halogenated 2,4-Diphenyl Indeno[1,2-b]pyridinol Derivatives as Potent Topoisomerase IIα-targeted Agents for Breast Cancer” J. Med. Chem. 62 (2019), 8194. Link

11.    Kadayat TM et al. “Synthesis of Unique Dimethyl Thiazoline Core Containing Intermediate of Novel PPARd agonists” Tetrahedron Lett. 59 (2018), 4384. Link

12.    Lee SJ, Samala M, Woo SY, Kadayat TM et al. “Enantioselective Synthesis of a Novel Thiazoline Core as a Potent PPARδ Agonist” ACS Omega 3 (2018), 1970-1976. Link 

13.    Kadayat TM et al. “Discovery and SAR of 2-benzylidene-inden-1-one and benzofuranone derivatives as a novel class of potential therapeutics for inflammatory bowel disease” Eur. J. Med. Chem. 137 (2017), 575. Link

14. Jun K-Y, Park C, Kadayat TM et al. “Indeno [1, 2-b] pyridinone derivative, a novel DNA intercalative topoisomerase IIα catalytic inhibitor, with caspase 3-independent anticancer activity” Chem. Comm. 53 (2017), 6864. Link

15. Kwon HB, Park C, Jeon KW, Jun KY, Kadayat TM et al. “A series of novel terpyridine-skeleton molecule derivants inhibit tumor growth and metastasis by targeting topoisomerases” J. Med. Chem. 58 (2015) 1100. Link

16. Kadayat TM et al. “Hydroxylated 2,4-diphenylindenopyridine derivatives as a selective non-intercalative topoisomerase IIα catalytic inhibitor” Eur. J. Med. Chem. 90 (2015), 302. Link

Other Publication

17. Shrestha A, Hwang SY, Kunwar S, Kadayat TM et al. “Di-indenopyridines as topoisomerase II-selective anticancer agents: Design, Synthesis, and Structure-Activity Relationships” Bioorg. Med. Chem. 91(2023), 117403. Link

18. Kunwar S, Lee SM, Kadayat TM et al. “Potent inhibitory activity of hydroxylated naphthalenones on LPS-stimulated ROS production in RAW 264.7 macrophages” Bioorg. Med. Chem. Lett. 73 (2022), 128921. Link

19. Kunwar S, Hwang SY, Katila P, Kadayat TM et al. “Topoisomerase IIα inhibitory and antiproliferative activity of dihydroxylated fluorophenylpyridines: Design, synthesis, and SAR” Bioorg. Med. Chem. Lett. 60 (2022), 128606. Link

20. Hwang SY, Shrestha A, Park S, Bist G, Kadayat TM et al. “Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors” Eur. J. Med. Chem. 227 (2022), 113916. Link

21. Kunwar S, Hwang SY, Katila P, Kim D, Kadayat TM et al. “Discovery of 2, 4-diphenyl-5, 6-dihydrobenzo (h) quinolin-8-amine derivatives as DNA intercalating topoisomerase IIα targeted novel chemotherapeutic agents” Eur. J. Med. Chem. 226 (2021), 113860. Link

22. Kunwar S, Hwang SY, Katila P, Kadayat TM et al. “4-Flourophenyl-substituted 5H-indenopyridinols with enhanced topoisomerase IIα inhibitory activity: Synthesis, biology, and SAR” Bioorg. Chem. 116 (2021), 105349. Link

23. Kim J, Hwang H, Yon H, Lee SJ, Kadayat TM et al.  “An Orally Available Inverse Agonist of ERRg Showed Expanded Efficacy for the Radioiodine Therapy of Poorly Differentiated Thyroid Cancer” Eur. J. Med. Chem. 205 (2020), 112501. Link

24. Shrestha A, #Kadayat TM (#Editorial) “Drug Discovery and Development Strategies for COVID-19” Europasian J. Med. Sci. 2 (2020), 1. Link

25. Kadayat TM et al. “Synthesis and biological evaluation of pyridine-linked indanone derivatives: Potential agents for inflammatory agents” Bioorg. Med. Chem. Lett. 28 (2018), 2436. Link

26. Kim DS, Lee J, Londhe AM, Kadayat TM et al. “Synthesis and evaluation of an orally available ‘Y”-shaped biaryl peroxisome proliferator-activated receptor d agonist” Bioorg. Med. Chem. 26 (2018), 4382. Link

27. Shrestha A, Park S, Shin S, Kadayat TM et al. Design, synthesis, biological evaluation, SAR study, and mode of action of 2-phenol-4,6-dichlorophenyl-pyridines Bioorg. Chem. 79 (2018), 1.

28.    *Magar TBT, *Seo SH, *Kadayat TM et al. Synthesis and SAR study of new hydroxy and chloro-substituted-chromeno[4,3-b]pyridines as selective topoisomerase IIα-targeting anticancer agents Bioorg. Med. Chem. 26 (2018) 1909.

29.    Gurung P, Banskota S, Katila N, Gautam J, Kadayat TM et al. Ameliorating effect of TI-1-162, a hydroxyindenone derivative, against TNBS-induced rat colitis is mediated through suppression of RIP/ASK-1/MAPK signaling Eur. J. Pharmacol. 827 (2018), 94. Link

30.    Park S, Magar TBT, Kadayat TM et al. “Rational design, synthesis, and evaluation of novel Chloro-and Hydroxy-Substituted diphenyl Benzofuropyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor” Eur. J. Med. Chem. 127 (2017), 318.

31.    *Park S, *Kadayat TM et al. “Novel 2-aryl-4-(4′-hydroxyphenyl)-5H-indeno [1, 2-b] pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors” Eur. J. Med. Chem. 125 (2017), 14.

32.    *Magar TBT, *Kadayat TM et al. “2-Chlorophenyl-substituted benzofuro [3, 2-b] pyridines with enhanced topoisomerase inhibitory activity: The role of the chlorine substituent,” Bioorg. Med. Chem. Lett. 27 (2017), 3279.

33.    *Magar TBT, *Kadayat TM et al. “Inhibitory Activity of Halogenated 3‐Benzylidenechroman‐4‐ones Against Lipopolysaccharide‐stimulated ROS Production in RAW 264.7 Macrophages” Bull. Korean Chem. Soc. 38 (2017) 665. 

34.    Kadayat TM et al. “Effect of chlorine substituent on cytotoxic activities: Design and synthesis of systematically modified 2,4-diphenyl-5H-indeno[1,2-b]pyridines” Bioorg. Med. Chem. Lett. 26 (2016), 1726.

35.    *Karki R, *Jun-KY, *Kadayat TM et al. “A new series of 2-phenol-4-aryl-6-chlorophenyl pyridines as dual topoisomerase I/II inhibitors: Synthesis, biology and 3D-QSAR study” Eur. J. Med. Chem. 113 (2016), 228.

36.    *Thapa P, *Kadayat TM et al. “Synthesis and biological evaluation of 2-phenol-4-chlorophenyl-6-aryl pyridines as topoisomerase II inhibitors and cytotoxic agents” Bioorg. Chem. 66 (2016), 145.

37.    Thapa P, Jun KY, Kadayat TM et al. “Design and synthesis of conformationally constrained hydroxylated 4-phenyl-aryl chromenopyridines as topoisomerase II-targeted antiproliferative agents” Bioorg. Med. Chem. 23 (2015), 6454. Link

38.    Kadayat TM et al.  “Modified 2, 4-diaryl-5H-indeno [1, 2-b] pyridines with hydroxyl and chlorine moiety: Synthesis, anticancer activity, and SAR study” Bioorg. Chem. 62 (2015), 30.

39.    Kadayat TM et al. “Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and SAR study of 2-phenyl- or hydroxylated 2-phenyl-4-aryl-5H-indeno[1,2-b]pyridines” Bioorg. Med. Chem. 23 (2015), 3499.

40.    Karki R, Song C, Kadayat TM et al. “Topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of dihydroxylated 2,6-diphenyl-4-aryl pyridines” Bioorg. Med. Chem. 23 (2015), 3638.

41.    *Kim MJ, *Kadayat TM et al. TI-I-174, Inhibitory Effect of Hydroxyphenyl-propeone, a Chalcone Derivative on MCP-1 Expression in Macrophages via Inhibition of ROS and Akt Signaling Biomol. Therap. 23 (2015), 119.

42.    Kadayat TM et al. “Design and synthesis of novel 2,4-diaryl-5H-indeno[1,2-b]pyridine derivatives, and their evaluation of topoisomerase inhibitory activity and cytotoxicity” Bioorg. Med. Chem. 23 (2015), 160. Link

43.    Karki R, Park C, Kadayat TM et al. “Synthesis and biological activity of 2,4-Di-p-phenolyl-6-2-furanyl-pyridine as a potent topoisomerase II poison” Eur. J. Med. Chem. 90 (2015), 360.

44.    *Kim MJ, *Kadayat TM et al. TI-I-174, a Synthetic Chalcone Derivative, Suppresses Nitric Oxide Production in Murine Macrophages via Heme Oxygenase-1 Induction and Inhibition of AP-1 Biomol. Ther. 22 (2014), 390.

45.    *Kadayat TM, *Kim MJ et al. “Thieny/Furanyl hydroxyphenylpropenones as Inhibitors of LPS-induced ROS and NO Production in RAW 264.7 Macrophages, and Their SAR Study” Bull. Korean Chem. Soc. 35 (2014) 2481.

46. Karki R, Park C, Jun KY, Jee JG, Lee JH, Thapa P, Kadayat TM et al. Synthesis, antitumor activity, and SAR of trihydroxylated-triphenylpyridines as potent and selective topoisomerase II inhibitor Eur. J. Med. Chem. 84 (2014), 555.

47.    Thapa P, Karki R, Yun M, Kadayat TM et al. “Design, synthesis, and antitumor evaluation of 2,4,6-triaryl pyridines containing chlorophenyl and phenolic moiety” Eur. J. Med. Chem. 52 (2012), 123.

48.    Karki R, Thapa P, Yoo HY, Kadayat TM et al. “Dihydroxylated 2,4,6-triphenyl pyridines: Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure activity relationship study” Eur. J. Med. Chem. 49, (2012), 219.

49.    *Kadayat TM et al. “Patterns and perception of complementary and alternative medicine use by patients in western Nepal” J. Public Health 20 (2012), 297. Link

50.    *Kadayat TM et al. Complementary and Alternative Medicine in Nepal J Med. Use Dev. Count. 1, (2009) 3. Link

Selected Presentations

Invited Oral Presentations

1.      Kadayat TM (Invited Talk) ‘Rational and Structure-Guided Drug Discovery for Cancer Therapy.’ FIU BSI Seminar (September 12, 2025, Miami, USA).

2.      Kadayat TM (Invited Talk) ‘Drug Discovery and Development.’ LUSRP Professional Development Session (June 13, 2025, Miami, USA).

3.      Kadayat TM (Invited Talk) ‘Targeting the Neddylation Pathway: TK-59 as Potent DCN1 Inhibitor for Cancer Therapy.’ ACS National Meeting (March 27, 2025, San Diego, USA).

4.      Kadayat TM  (Invited Talk)  ‘Protein-Protein Interaction Inhibitors for Lung Cancer.’ Global Korea Scholarship (GKS) Alumni Nepal Symposium (Nov 10, 2024, Kathmandu, Nepal).

5.      Kadayat TM (Invited Talk) ‘Bridged Piperidines as Inhibitors of Neddylation E3 Ligase Inhibitors.’ Amgen Chemistry Day (Sept 20, 2024, Thousand Oaks, USA).

6.      Kadayat TM (Invited Talk)   ‘Medicinal Chemistry of Cell Wall Inhibitors.’ Larkin University (Sept 23, 2024, FL, USA).

7.       Kadayat TM  (Invited Talk)  ‘Shark Tank Presentation.’ University of Kentucky Graduate Retreat’ (August 8, 2024, KY, USA).

8.      Kadayat TM (Invited Talk) ‘Development of Small Molecule Therapeutics for Lung Cancer.’ NSF Regional I-Corps (June 28, 2024, KY, USA).

9.       Kadayat TM (Invited Talk)  ‘Medicinal Chemistry of Beta-Lactams.’ Virginia Commonwealth University (June 5, 2024, VA, USA).

10.   Kadayat TM (Invited Talk) ‘UKCOM Dean’s Distinguished Lecture Series.’ University of Kentucky (May 15, 2024, KY, USA).

11.  Kadayat TM (Invited Talk) ‘Rational Drug Discovery for Cancer and Neglected Disease.’ NIH (Nov. 7, 2023, MD, USA).

12.  Kadayat TM (Invited Talk)  ‘TK-006: Unveiling the Journey of Anticancer Agent.’ Postdoc Talk Competition (Sept. 21, 2023, KY, USA).

Contributed Oral Presentations

13.  Kadayat TM (Contributed Talk) ‘Targeting Neddylation Pathway for Anticancer Drug.’ University of Kentucky Pharmaceutical Science Seminar (Sept. 19, 2023, KY, USA).

14.  Kadayat TM (Contributed Talk)  ‘Development of Potent NEDD8-Activating Enzyme Inhibitors.’ University of Kentucky Pharm. Sci. Super Group Meeting (Feb. 9, 2023, KY, USA).

15.  Kadayat TM (Contributed Talk) ‘Approaches to Targeting NSD2 Histone Lysine Methyltransferases.’ University of Kentucky Slice of Science 5-minute Chalk Talk (Sept. 22, 2022, KY, USA).

16.  Kadayat TM (Contributed Talk)  ‘Challenges and Opportunities for Independent Researchers in Korea: A Personal Reflection.’ SONSIK Annual Seminar (March 17, 2021, South Korea).

Selected Poster Presentations

1.      Brouri M, Nirob FM, Kadayat TM, “Targeting HDAC8: Computational Drug Discovery of Selective HDAC8 PROTACs” SERMACS/SWRM 2025 Meeting (October 26, 2025, Orlando).

2.      Nirob FM, Brouri M, Kadayat TM, “Rational Design of Selective HDAC8 Inhibitor as Anticancer Agent” 135th Florida Pharmacy Association Annual Meeting, the Gordon Research Conference- Medicinal Chemistry (July 17, 2025, Orlando).

3.      Kadayat TM Gordon Research Conference- Bioorganic Chemistry (June 9, 2024, Andover). 

4.      Kadayat TM Annual Trainee Research Day University of Kentucky (April 8, 2024, Lexington).

5.      Kadayat TM Gordon Research Conference- Medicinal Chemistry (August 6, 2023, New London).

6.      Kadayat TM ACSMEDI-AFMC Frontiers in Medicinal Chemistry (June 10-13, 2023, Boston).

7.      Kadayat TM Markey Cancer Center Research Day (May 12, 2023, Lexington).

8.      Kadayat TM 37th ACS National Medicinal Chemistry Symposium, (June 26, 2022, New York).